文献速递淋巴瘤

免疫缺陷、疾病特征与患者特征对浆母细胞淋巴瘤生存的影响

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.
PubMed 文献 · Blood · 2024-01-01

这项多中心国际回顾性队列研究纳入4国22家机构1999年1月1日至2020年12月31日诊断的281例浆母细胞淋巴瘤患者,中位年龄55岁,51%存在免疫缺陷、35% HIV阳性,5年总生存率36%(95%CI 30%-42%)。多因素分析显示EB病毒阴性淋巴瘤、体能状态差、晚期分期和骨髓受累与更差总生存相关;免疫抑制或HIV感染本身未影响总生存;在234例以治愈为目的治疗的患者中,总缓解率72%,一线方案强度或是否含蛋白酶体抑制剂与总生存无关。

要点

  • 281例浆母细胞淋巴瘤患者5年总生存率为36%(95%CI 30%-42%)。
  • EB病毒阴性、体能状态差、晚期分期和骨髓受累与更差总生存相关。
  • 免疫抑制或HIV感染本身未影响总生存,一线方案强度及含蛋白酶体抑制剂与总生存无关。

核心结论

  • 在这项大型回顾性研究中,研究者识别出浆母细胞淋巴瘤新的生存风险因素,该病仍是长期结局不佳的挑战性疾病。

研究设计与样本

  • 多中心、国际、回顾性队列研究,收集4个国家22家机构1999年1月1日至2020年12月31日诊断的浆母细胞淋巴瘤患者资料。
  • 共纳入281例患者,中位年龄55岁;采用单因素和多因素回归模型分析生存风险因素,Kaplan-Meier法计算总生存。

主要发现

  • 144例(51%)存在任何类型的免疫缺陷,99例(35%)HIV阳性。
  • 整个队列5年总生存率为36%(95%CI 30%-42%)。
  • 多因素分析中,EB病毒阴性淋巴瘤、体能状态差、晚期分期和骨髓受累与更差总生存相关。
  • 独立单因素分析中,国际预后指数与总生存结局相关。
  • 免疫抑制或HIV感染本身未影响总生存。

关键数值与推荐

  • 一线治疗方案被分层为标准强度和高强度方案,并按是否含蛋白酶体抑制剂(PI)分层。
  • 总生存采用Kaplan-Meier统计计算。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated with immunodeficiency, characterized by uncertain treatment approaches and an unfavorable prognosis. We conducted a multicenter, international, retrospective cohort study, aiming to characterize the clinical features, risk factors, and outcomes of patients with PBL. Data were collected from 22 institutions across 4 countries regarding patients diagnosed with PBL between 1 January 1999 and 31 December 2020. Survival risk factors were analyzed using both univariate and multivariate regression models. Overall survival (OS) was calculated using Kaplan-Meier statistics. First-line treatment regimens were stratified into standard- and higher-intensity regimens, and based on whether they incorporated a proteasome inhibitor (PI). A total of 281 patients (median age, 55 years) were included. Immunodeficiency of any kind was identified in 144 patients (51%), and 99 patients (35%) had HIV-positive results. The 5-year OS for the entire cohort was 36% (95% confidence interval, 30%-42%). In multivariate analysis, inferior OS was associated with Epstein-Barr virus-negative lymphoma, poor performance status, advanced stage, and bone marrow involvement. In an independent univariate analysis, the international prognostic index was associated with OS outcomes. Neither immunosuppression nor HIV infection, specifically, influenced OS. Among patients treated with curative intent (n = 234), the overall response rate was 72%. Neither the intensity of the treatment regimen nor the inclusion of PIs in first-line therapy was associated with OS. In this large retrospective study of patients with PBL, we identified novel risk factors for survival. PBL remains a challenging disease with poor long-term outcomes.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Di Ciaccio PR, Polizzotto MN, Cwynarski K, et al. The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Blood. 2024. PMID: 37832030. doi:10.1182/blood.2023021348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。